Tarsons Products Limited announced Q1 financial results with 7.7% YoY revenue growth to ₹913.64 crore on a consolidated basis. Standalone revenue grew 9.9% YoY to ₹712.79 crore, with domestic revenue up 12.3%. However, net profit declined to ₹17.83 crore from ₹40.16 crore YoY. The profitability drop is attributed to higher depreciation from the capitalization of the new Panchla facility. Management remains optimistic about future growth prospects, citing a strong order pipeline and potential from new product categories.
04Aug 25
Tarsons Products Reshapes Board with Strategic Appointments and Resignations
Tarsons Products Limited has announced significant changes to its board composition, effective August 4, 2025. Dr. Monjori Mitra, with 24 years of experience in infectious diseases and pediatrics, has been appointed as Additional Director (Non-Executive Independent). Mr. Ramanathan Subramanian Arun Kumar, representing Clear Vision Investment Holdings Pte Ltd, joins as Additional Director (Non-Executive Nominee). Mr. Suresh Eshwara Prabhala has resigned as Non-Executive Nominee Director but has been reappointed as Additional Director (Non-Executive Non-Independent). These appointments bring diverse expertise in medicine, finance, and corporate strategy to the company's leadership.
23Jul 25
Tarsons Products Appoints Divya Sameer Momaya as Independent Director with Overwhelming Shareholder Approval
Tarsons Products Limited has appointed Mrs. Divya Sameer Momaya as a Non-Executive Independent Director for a five-year term starting May 24, 2025. The appointment received overwhelming shareholder approval with 99.99% of votes in favor. Mrs. Momaya brings over 22 years of experience in corporate law, governance, and business development. She holds a Bachelor's degree in Commerce and is an Associate Member of the Institute of Company Secretaries of India.
28May 25
Tarsons Products Q4 Revenue Climbs, Profit Dips
Tarsons Products reported mixed Q4 results. Revenue increased 7.39% to ₹930.00 million, and EBITDA rose 9.14% to ₹370.00 million with an improved margin of 39.73%. However, standalone net profit declined 16.49% to ₹157.00 million compared to the previous year.
09Apr 25
Tarsons Products Settles €15 Million Earn-Out Obligation Ahead of Schedule
Tarsons Products Limited, an Indian laboratory plasticware manufacturer, has announced the early settlement of a €15 million earn-out obligation. The company pre-closed and discharged this obligation, which was initially issued as a corporate guarantee to PN Beteiligugns GmbH on behalf of its Singapore subsidiary, Tarsons Life Science Pte. Ltd. This transaction has been reported to the Reserve Bank of India, demonstrating regulatory compliance. The early settlement potentially improves Tarsons' financial flexibility, demonstrates financial strength, and reduces its liabilities.